MedTrace Logo

Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane

NCT02728622 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2016-04-05

No results posted yet for this study

Summary

A randomized study of chemotherapy versus hormonal treatment in patients with ovarian cancer resistant or refractory to platinum and taxane.

Conditions

Interventions

DRUG

Tamoxifen

endocrine treatment

DRUG

Chemotherapy

Paclitaxel or pegylated liposomal doxorubicin

Sponsors & Collaborators

  • Nordic Society of Gynaecological Oncology - Clinical Trials Unit

    lead OTHER

Principal Investigators

  • Gunnar B Kristensen, Prof · The Norwegian Radium Hospital, Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2008-01-31
Completion
2009-01-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02728622 on ClinicalTrials.gov